(Q37404485)

20 August 2017

1 reference

title

New approaches for managing antiphospholipid syndrome (English)

1 reference

20 August 2017

2

Michael D Lockshin

1 reference

20 August 2017

1

Doruk Erkan

1 reference

20 August 2017

publication date

1 March 2009

1 reference

Nature Clinical Practice Rheumatology

20 August 2017

published in

1 reference

20 August 2017

volume

5

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

160-170

1 reference

Thrombophilia and new anticoagulant drugs

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM1017

Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM1017

New targeted therapies for treatment of thrombosis in antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM1017

Tissue factor in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM1017

Angiotensin-Converting Enzyme Inhibitors Downregulate Tissue Factor Synthesis in Monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM1017

Elevated Levels of Interleukin-6 in Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM1017

Management of antiphospholipid antibody syndrome: a systematic review

21 January 2018

1 reference

12 December 2020

A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma

1 reference

12 December 2020

Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies

1 reference

12 December 2020

Complement activation in patients with primary antiphospholipid syndrome

1 reference

12 December 2020

Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies

1 reference

12 December 2020

Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty

1 reference

12 December 2020

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

1 reference

12 December 2020

The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome

1 reference

12 December 2020

The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation

1 reference

12 December 2020

Long term outcome of catastrophic antiphospholipid syndrome survivors

1 reference

12 December 2020

Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke

1 reference

12 December 2020

Real world experience with antiphospholipid antibody tests: how stable are results over time?

1 reference

12 December 2020

Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant

1 reference

12 December 2020

TNFalpha DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome.

1 reference

12 December 2020

The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases

1 reference

12 December 2020

Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome

1 reference

12 December 2020

Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells

1 reference

12 December 2020

A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome

1 reference

12 December 2020

New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

1 reference

12 December 2020

Interleukin-6 and antiphospholipid antibodies in women with contraceptive-related thromboembolic disease

1 reference

12 December 2020

Prevention of murine antiphospholipid syndrome by BAFF blockade

1 reference

12 December 2020

Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype

1 reference

12 December 2020

Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model

1 reference

12 December 2020

Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties.

1 reference

12 December 2020

Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events

1 reference

12 December 2020

Warfarin and the antiphospholipid syndrome: does one size fit all?

1 reference

12 December 2020

A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome

1 reference

12 December 2020

Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation

1 reference

12 December 2020

Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers

1 reference

12 December 2020

Catastrophic antiphospholipid syndrome

1 reference

12 December 2020

Obstetric uses of intravenous immunoglobulin: successes, failures, and promises

1 reference

12 December 2020

Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?

1 reference

12 December 2020

Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype

1 reference

12 December 2020

Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids

1 reference

12 December 2020

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.

1 reference

12 December 2020

Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin

1 reference

12 December 2020

Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia

1 reference

12 December 2020

Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature.

1 reference

12 December 2020

The management of thrombosis in the antiphospholipid-antibody syndrome

1 reference

12 December 2020

Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti-β2-Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β2-Glycoprotein I and Induce Endothelial Activation

1 reference

12 December 2020

Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy.

1 reference

12 December 2020

CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice

1 reference

12 December 2020

The antiinflammatory activity of IgG: the intravenous IgG paradox

1 reference

12 December 2020

Innate immune response gene expression profiles characterize primary antiphospholipid syndrome.

1 reference

12 December 2020

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

1 reference

12 December 2020

A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies

1 reference

12 December 2020

Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines

1 reference

12 December 2020

Controversies in the antiphospholipid syndrome: can we ever stop warfarin?

1 reference

12 December 2020

NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies.

1 reference

12 December 2020

The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients

1 reference

12 December 2020

Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone

1 reference

12 December 2020

Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies

1 reference

12 December 2020

TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss

1 reference

12 December 2020

Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals

1 reference

12 December 2020

The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus.

1 reference

12 December 2020

Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator

1 reference

12 December 2020

Primary prevention of ischemic stroke

1 reference

12 December 2020

Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort

1 reference

12 December 2020

New approaches to prevention of thrombosis in the antiphospholipid syndrome: Hopes, trials, and tribulations

1 reference

12 December 2020

Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.

1 reference

12 December 2020

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

12 December 2020

Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T

1 reference

12 December 2020

Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro

1 reference

12 December 2020

What is antiphospholipid syndrome?

1 reference

12 December 2020

Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers

1 reference

12 December 2020

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

1 reference

12 December 2020

On the inhibitory effect of chloroquine on blood platelet aggregation

1 reference

12 December 2020

Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies

1 reference

12 December 2020

Identifiers

DOI

10.1038/NCPRHEUM1017

1 reference

20 August 2017

1 reference